Page last updated: 2024-10-28
ifosfamide and Alzheimer Disease
ifosfamide has been researched along with Alzheimer Disease in 1 studies
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
Research Excerpts
| Excerpt | Relevance | Reference |
|---|
| " At present, MB is the first line of treatment in methemoglobinemias, is used frequently in the treatment of ifosfamide-induced encephalopathy, and is routinely employed as a diagnostic tool in surgical procedures." | 4.87 | Cellular and molecular actions of Methylene Blue in the nervous system. ( Hasan, M; Lorke, DE; Oz, M; Petroianu, GA, 2011) |
Research
Studies (1)
| Timeframe | Studies, this research(%) | All Research% |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|
| Oz, M | 1 |
| Lorke, DE | 1 |
| Hasan, M | 1 |
| Petroianu, GA | 1 |
Clinical Trials (1)
Trial Overview
| Trial | Phase | Enrollment | Study Type | Start Date | Status |
|---|
| Treatment in Outpatient Patients With Covid-19 With Methylene Blue and Photodynamic[NCT04619290] | Phase 1 | 46 participants (Anticipated) | Interventional | 2020-10-12 | Recruiting |
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Reviews
1 review available for ifosfamide and Alzheimer Disease